# US 2004/0082041 A1 · Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082041 A1
- Document ID: US20040082041A1
- Status: Published application
- Kind: A1
- Application number: 10/720,824
- Filed: 2003-11-24
- Published: 2004-04-29
- Earliest claimed: 1991-11-19
- Assignees: SmithKline Beecham Corporation
- Inventors: Richard Mark Hindley; Stefan Roland Woroniecki
- Web page: https://patentgrep.com/patent/US20040082041A1

## CPC

- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C12P 17/14: Nitrogen or oxygen as hetero atom and at least one other diverse hetero ring atom in the same ring
- C12P 17/16: containing two or more hetero rings {(thiamine open chain analogs C12P17/167, i.e. not condensed among themselves or through a common carbocyclic ring system)}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

1 A process for preparing a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein: T represents a substituted or unsubstituted aryl group and T1 is O or S; which process comprises, treating a compound of formula (II), or a tautomeric form thereof and/or a salt thereof and/or a solvate thereof, wherein T and T1 are as defined in relation to formula (I), with a microbial reductase obtained from an appropriate red yeast; and thereafter, as required, preparing a pharmaceutically acceptable salt and/or a pharmaceutically acceptable solvate of the compound of formula (I) or a tautomeric form thereof; compounds prepared by such a process and the use of such compounds in medicine.

## Claims

### Claim 1

A process for preparing a compound of formula (I):
26
or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein:
T represents a substituted or unsubstituted aryl group and T1 is O or S;
which process comprises, treating a compound of formula (II):
27
or a tautomeric form thereof and/or a salt thereof and/or a solvate thereof, wherein T and T1 are as defined in relation to formula (I), with a microbial reductase obtained from an appropriate red yeast; and thereafter, as required, preparing a pharmaceutically acceptable salt and/or a pharmaceutically acceptable solvate of the compound of formula (I) or a tautomeric form thereof.

### Claim 2 (depends on 1)

A process according to claim 1, wherein T represents a moiety selected from the list consisting of (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Il), (Im), (In), (Io) and (Ip):
28
wherein A1, A2, R1 and n are as defined in relation to formula (I) of EP 0306228;
29
wherein R2, L1, L2 and L3 are as defined in relation to formula (I) of EP 0008203;
30
wherein R1, R2, R3, R4, R5, W and n are as defined in relation to formula (I) of EP 0139421;
31
wherein R1, R2 and R3 are as defined in relation to formula (I) of EP 0032128;
32
wherein A, R, R1 and X are as defined in relation to formula (I) of EP 0428312;
33
when A, B, R and R1 are as defined in relation to formula (II) of EP 0428312;
34
wherein R1 is as defined in relation to formula (I) of EP 0489663;
35
wherein R1, R2, R3 and n are as defined in relation to formula (I) of EP 0155845;
36
when R1 is as defined in relation to formula (I) of EP 0257781;
37
wherein Ar, R1, R2, R3, R4, R5, n, U and W are as defined in relation to formula (I) of U.S. Pat. No. 5,104,888;
38
when A, R1, R2 and X are as defined in relation to formula (I) of EP 0208420;
39
when R1, R2, X, Z m and n are as defined in relation to formula (I) of EP 0177353;
40
according to formula (I) of EP 0319189;
41
wherein A, B, X, X1, X2, n and Z are as defined in relation to formula (I) of EP 0332331;
42
wherein V, W, X, Y, Z, Z1 and n are as defined in EP 0332332; and
43
wherein Q and X are as defined in relation to formula (I) of International Application No. WO 92/18501.

### Claim 3 (depends on 1, 2)

A process according to claim 1 or claim 2, wherein T represents a moiety selected from the list consisting of (a), (b), (c), (d), (e), (f), (g), (h) and (i):
44

### Claim 4 (depends on 1, 2, 3)

A process according to any one of claims 1 to 3, wherein T represents a moiety of formula (Ia).

### Claim 5 (depends on 1, 2, 3, 4)

A process according to any one of claims 1 to 4, wherein T1 represents S.

### Claim 6 (depends on 1)

A process according to claim 1 for the preparition of a compound of formula (1):
45
or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein:
A1 represents a substituted or unsubstituted aromatic heterocyclyl group;
R1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group;
A2 represents a benzene ring having in total up to five substituents; and
n represents an integer in the range of from 2 to 6;
which process comprises, treating a compound of formula (2):
46
or a tautomeric form thereof and/or a salt thereof, and/or a solvate thereof, wherein A1, A2, R1 and n are as defined in relation to formula (1) with a microbial reductase obtained from an appropriate red yeast; and thereafter, as required, preparing a pharmaceutically acceptable salt, and/or a pharmaceutically acceptable solvate of the compound of formula (1) or a tautomeric form thereof.

### Claim 7 (depends on 6)

A process according to claim 6, wherein the compound of formula (1) is 5-(4-[2-N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-2,4-thiazolidinedione, or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

A process according to any one of claims 1 to 7, wherein an appropriate red yeast is a red yeast which provides the above mentioned reduction, including known red yeasts and those red yeasts which may be produced from known red yeasts by conventional methods.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A process according to any one of claims 1 to 8, wherein an appropriate red yeast is a red yeast from the species of the genera Rhodotorula, Rhodosporidium or synonyms thereof.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A process according to any one of claims 1 to 9 wherein an appropriate red yeast is Rhodotorula glutinis CBS 4406, Rhodotorula rubra CBS 6469, Rhodotorula rubra CBS 17 and Rhodotorula glutinis IFO 0869.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A process according to any one of claims 1 to 9 wherein an appropriate red yeast is Rhodosporidium toruloides CBS 14

### Claim 12

A process for the preparation of a compound of formula (I) (the ‘enantiomerically enriched compound (I)’) wherein greater than 50% w/w of said compound is in the form of a compound of formula (IA):
47
or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein T and T1 are as defined in relation to formula (I) and the ‘**’ carbon atom is an enantiomeric carbon atom, which process comprises reacting a compound of the above defined formula (II) with a microbial reductase obtained from an appropriate red yeast and wherein the reaction is carried out at an acidic pH; and thereafter, as required, preparing a pharmaceutically acceptable salt and/or a pharmaceutically acceptable solvate of the enantiomerically enriched compound (I) or a tautomeric form thereof.

### Claim 13

Enantiomerically enriched compound (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, wherein greater than 50% w/w is in the form of compound (IA)

### Claim 14

A compound of formula (IA) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, in optically pure form.

### Claim 15

Enantiomerically enriched compound (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use as an active therapeutic substance.

### Claim 16

Enantiomerically enriched compound (I), or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of hyperglycaemia, hyperlipidaemia, hypertension, cardiovascular disease and certain eating disorders.

### Claim 17

A pharmaceutical composition comprising enantiomerically enriched compound (I), or a tautomeric form thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.
